Results 91 to 100 of about 15,126 (225)
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Journal of Eating DisordersBackground Clinical trials using psilocybin therapy to treat anorexia nervosa (AN) are currently underway. The safety and tolerability of psilocybin is of utmost importance in individuals with AN who may present unique medical vulnerabilities.
Amanda E. Downey +3 more
doaj +1 more source
Ocular sequelae from the illicit use of class A drugs [PDF]
, 2004 Aim: To highlight the changes that may take place in the visual system of the class A drug abuser. Methods: A literature review was carried out of ocular/visual sequelae of the more common class A drugs.
Firth, A.Y.
core
Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials
British Journal of Pharmacology, EarlyView.Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen +2 more
wiley +1 more source
Scientific ReportsMajor depressive disorder (MDD) is a leading cause of disability that affects over 300 million people globally. Despite multiple antidepressant trials, approximately one-third of MDD patients remain symptomatic, progressing to treatment-resistant ...
Zitong Wang +6 more
doaj +1 more source
Journal of Applied Philosophy, EarlyView.ABSTRACT Psychedelics offer an intriguing novel method for changing minds, supposedly by destabilizing the neurobiology of the belief system. The resulting power to change minds raises ethical and epistemic concerns. This article examines the epistemic status of psychedelic experiences and suggests a skeptical attitude towards beliefs formed under ...
Jan Christoph Bublitz
wiley +1 more source
Translational PsychiatryDepression and anxiety are disabling and high incidence mental disorders characterized by phenotypic heterogeneity. Currently available treatments show severe limitations. Thus, there is an urgent need for effective treatments in this population.
Ines Erkizia-Santamaría +7 more
doaj +1 more source
Topics in Cognitive Science, EarlyView.Abstract This manuscript documents a systematic ethnomycological analysis of ethnographic archives. Focusing on texts describing human–fungi interactions, I conduct a global, cross‐cultural review of mushroom use, covering 193 societies worldwide. The study reveals diverse mushroom‐related cultural practices, emphasizing the significance of fungi ...
Roope O. Kaaronen
wiley +1 more source
The Great God Pan is Not Dead – A. N. Whitehead and the Psychedelic Mode of Perception [PDF]
, 2017 Through Alfred North Whitehead’s metaphysics, the Philosophy of Organism, it will be argued that psychedelic experience is a vertical, lateral and temporal integration of ...
Sjöstedt-H., Peter
core
Adolescent brain cognitive development (ABCD) study: Overview of substance use assessment methods. [PDF]
, 2018 One of the objectives of the Adolescent Brain Cognitive Development (ABCD) Study (https://abcdstudy.org/) is to establish a national longitudinal cohort of 9 and 10 year olds that will be followed for 10 years in order to prospectively study the risk and
Bartsch, Hauke +9 more
core +2 more sources